Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide.
+ 2 more risks
Mediocre balance sheet and overvalued.
Share Price & News
How has Onxeo's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OXNX.F has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how OXNX.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how OXNX.F performed against the US Market.
Price Volatility Vs. Market
How volatile is Onxeo's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Onxeo undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OXNX.F's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OXNX.F's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OXNX.F is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: OXNX.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OXNX.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OXNX.F is good value based on its PB Ratio (0.8x) compared to the US Biotechs industry average (3.2x).
How is Onxeo forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OXNX.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OXNX.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OXNX.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OXNX.F's revenue is expected to decline over the next 3 years (-33.7% per year).
High Growth Revenue: OXNX.F's revenue is forecast to decline over the next 3 years (-33.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OXNX.F's Return on Equity is forecast to be high in 3 years time
How has Onxeo performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OXNX.F is currently unprofitable.
Growing Profit Margin: OXNX.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OXNX.F is unprofitable, and losses have increased over the past 5 years at a rate of -17.6% per year.
Accelerating Growth: Unable to compare OXNX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OXNX.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).
Return on Equity
High ROE: OXNX.F has a negative Return on Equity (-23.24%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Onxeo's financial position?
Financial Position Analysis
Short Term Liabilities: OXNX.F's short term assets (€13.4M) exceed its short term liabilities (€7.9M).
Long Term Liabilities: OXNX.F's short term assets (€13.4M) exceed its long term liabilities (€12.1M).
Debt to Equity History and Analysis
Debt Level: OXNX.F's debt to equity ratio (19%) is considered satisfactory.
Reducing Debt: OXNX.F's debt to equity ratio has increased from 0.2% to 19% over the past 5 years.
Inventory Level: OXNX.F has a low level of unsold assets or inventory.
Debt Coverage by Assets: OXNX.F's debt is covered by short term assets (assets are 1.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OXNX.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OXNX.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.1% each year
What is Onxeo's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate OXNX.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OXNX.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OXNX.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OXNX.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OXNX.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Judith Greciet (51yo)
Ms. Judith Greciet, Ph.D., Pharmacy, has been the Chief Executive Officer of Onxeo SA (alternate name BioAlliance Pharma) since June 29, 2011. Ms. Greciet served as the Chief Operations Officer - Operation ...
CEO Compensation Analysis
Compensation vs Market: Judith's total compensation ($USD596.62K) is about average for companies of similar size in the US market ($USD521.92K).
Compensation vs Earnings: Judith's compensation has been consistent with company performance over the past year.
|CEO & Director||8.7yrs||€550.68k||0.19% €68.5k|
|CFO & Administrative and Finance Director||13.3yrs||no data||no data|
|Chief Scientific Officer||2.9yrs||no data||no data|
|Director of Human Resources||5yrs||no data||no data|
|Chief Pharmacist & Quality Assurance Director||0yrs||no data||no data|
|Chief of US Operations & Executive VP||3.9yrs||no data||no data|
|Chief Medical Officer||2.9yrs||no data||no data|
Experienced Management: OXNX.F's management team is considered experienced (4.5 years average tenure).
|CEO & Director||8.7yrs||€550.68k||0.19% €68.5k|
|Independent Director||7.8yrs||€13.95k||no data|
|Independent Director||3.8yrs||€9.45k||no data|
|Chairman of Scientific Advisory Board||2.3yrs||no data||no data|
|Independent Director||2.8yrs||€10.45k||no data|
|Member of Scientific Advisory Board||2.3yrs||no data||no data|
|Independent Director||3.8yrs||€8.20k||no data|
|Representative Director||8.7yrs||no data||0.066% €24.2k|
|Independent Chairman||0.8yrs||€10.95k||0.062% €22.5k|
|Independent Director||2.8yrs||€11.45k||no data|
Experienced Board: OXNX.F's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.
Onxeo SA's company bio, employee growth, exchange listings and data sources
- Name: Onxeo SA
- Ticker: OXNX.F
- Exchange: OTCPK
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €33.615m
- Listing Market Cap: €36.419m
- Shares outstanding: 61.01m
- Website: https://www.onxeo.com
Number of Employees
- Onxeo SA
- 49, boulevard du Général Martial Valin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ONXEO||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Dec 2005|
|C4X||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2005|
|0NWK||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Dec 2005|
|OXNX.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Dec 2005|
|ONXEO||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Ordinary Shares||DK||DKK||Dec 2005|
|ONXEOP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Dec 2005|
Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in clinical development stage for the treatment of metastatic melanoma; and Validive, which completed Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is based in Paris, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/18 00:45|
|End of Day Share Price||2019/12/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.